{
    "clinical_study": {
        "@rank": "98955", 
        "arm_group": [
            {
                "arm_group_label": "Phase I part :Systemic Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Lapatinib\nDrug: Lipo-Dox"
            }, 
            {
                "arm_group_label": "Phase II part", 
                "arm_group_type": "Experimental", 
                "description": "Drug: Lapatinib\nDrug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
            }
        ], 
        "brief_summary": {
            "textblock": "Objectives:\n\n      Phase I part\n\n        -  Primary Objective: To determine the recommended dose of the combination of lapatinib\n           with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive metastatic\n           breast cancer.\n\n        -  Secondary Objectives:To define the safety profile; To observe the response rate and\n           progression free survival\n\n      Phase II part\n\n        -  Primary Objective :To determined the objective response rate of the combination of\n           lapatinib with Lipo-Dox as first line chemotherapy in patients with ErbB2 positive\n           metastatic breast cancer.\n\n        -  Secondary Objectives:To define the safety profile; To determined the progression free\n           survival"
        }, 
        "brief_title": "ErbB2 Positive Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In phase I part Lapatinib (L) - dose level  I, II    1000mg po daily dose level  III, IV\n      1250mg po daily Intravenous Lipo Dox at the dose level reached on days 1 of a 21 days cycle\u2022\n      The recommended duration of combination treatment for each patient is at least 8 cycles,\n      then, with continue combination treatment cycles or single lapatinib treatment (start with\n      1500 mg per day) at investigator's discretion. The treatment will stop if progressive\n      disease, unacceptable toxicity or patient's refusal occurred. Intra patient escalation of\n      dose level is allowed if no major toxicity noted.\n\n      In phase II part Patients will receive recommended dose according to phase I study result.\n      The recommended duration of combination treatment for each patient is at least 8 cycles,\n      then, with continue combination treatment cycles or single lapatinib treatment (start with\n      1500 mg per day) at investigator's discretion. The treatment will stop if progressive\n      disease, unacceptable toxicity or patient's refusal occurred. Intra patient escalation of\n      dose level is allowed if no major toxicity noted."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the breast with evidence of metastatic\n             disease\n\n          -  Documented ErbB2 over expression or amplified disease in the invasive component of\n             the primary or metastatic lesion as defined by:\n\n          -  ErbB2 gene amplification by FISH(>6 ErbB2 gene copies per nucleus, or a FISH ratio\n             (ErbB2 gene copies to chromosome 17 signals) of >than 2.2;\n\n          -  Measurable disease, defined as \u22651 lesion that can be accurately measured in \u22651\n             dimension as \u226520 mm by conventional techniques OR as \u226510 mm by spiral CT scan\n\n          -  In phase II part, patients must be chemo-na\u00efve in metastatic setting.\n\n          -  In phase I part, patient may have received prior chemotherapy in metastatic setting.\n\n          -  In both phase I and II part, prior Anthracyclines allowed provided total dose of\n             doxorubicin hydrochloride \u2264240 mg/m\u00b2 or epirubicin \u2264 600 mg/m\u00b2.\n\n          -  At least 6 months since prior Anthracyclines, and 6 weeks since prior Taxane.\n\n          -  Patient must be informed and well understand that in current standard of treatment,\n             suggested first line treatments for erbB-2 positive, visceral organ metastatic breast\n             cancer are combination of chemotherapy with herceptin.\n\n          -  In phase II part, patient must not have exposed to ant-erbB2 targeted therapy\n             treatment in metastatic setting. Herceptin treatment in the neoadjuvant or adjuvant\n             setting is permitted provide that at least 12 months has elapsed since the last dose\n             of herceptin therapy.\n\n          -  In phase I part, patient may have received prior anti-erbB-2 targeted treatment in\n             metastatic setting.\n\n          -  Hormone receptor and menopausal status are not specified. Prior treatment with\n             endocrine therapy in the adjuvant or metastatic setting is permitted provided that\n             therapy be discontinued.\n\n          -  Prior treatments with radiation therapy for palliative management of non-target\n             lesion metastatic disease is permitted provided that at least 2 weeks have elapsed\n             since the last fraction of radiation therapy, disease progression has been documented\n             and all treatment related adverse events are \u2266 grade 1 at the time of registration.\n\n          -  Life expectancy \u2265 12 weeks\n\n          -  ECOG performance status 0-1\n\n          -  Patients must have normal organ and marrow function measured within 14 days prior to\n             study entry as defined below:\n\n          -  WBC \u2265 3,000/mm3\n\n          -  Absolute neutrophil count \u2265 1,500/mm3\n\n          -  Platelet count \u2265 100,000/mm3\n\n          -  Bilirubin normal\n\n          -  AST/ALT \u2264 2.5 times upper limit of normal\n\n          -  Normal serum creatinine  OR creatinine clearance \u226560 mL/min\n\n          -  LVEF \u2265 50% (by MUGA)\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  Able to swallow and retain  medication\n\n          -  No history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to lapatinib\n\n          -  Patient consent must be obtained.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women.\n\n          -  Subjects who have current active hepatic or biliary disease (with exception of\n             patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable\n             chronic liver disease per investigator assessment)\n\n          -  Prior therapy with concurrent use of Lapatinib.\n\n          -  CNS metastasis.\n\n          -  Ongoing other concurrent investigational agents or anticancer therapy\n\n          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable\n             angina pectoris, cardiac arrhythmia, serious non-healing wound/ulcer/bone fracture,\n             or psychiatric illness/social situations that would limit compliance with study\n             requirements.\n\n          -  Patients with GI tract disease resulting in an inability to take  medication,\n             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures\n             affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative\n             colitis)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658358", 
            "org_study_id": "EGF114081"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Phase I part :Systemic Therapy", 
                    "Phase II part"
                ], 
                "description": "dose level  I, II    1000mg po daily\ndose level  III, IV   1250mg po daily", 
                "intervention_name": "Lapatinib", 
                "intervention_type": "Drug", 
                "other_name": "Tykerb"
            }, 
            {
                "arm_group_label": [
                    "Phase I part :Systemic Therapy", 
                    "Phase II part"
                ], 
                "description": "at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,", 
                "intervention_name": "Lipo-Dox", 
                "intervention_type": "Drug", 
                "other_name": "Liposomal doxorubicin hydrochloride"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Lapatinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ErbB receptor", 
            "tyrosine kinase inhibitor", 
            "Anthracycline"
        ], 
        "lastchanged_date": "February 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taichung", 
                    "country": "Taiwan", 
                    "zip": "404"
                }, 
                "name": "China Medical University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I/II Study of Lapatinib (Tykerb) Plus Liposomal Doxorubicin Hydrochloride ( Lipo-Dox) for Patients With ErbB2 Positive Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "China Medical University Hospital", 
            "last_name": "Chang-Fang Chiu, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "-Phase I part: To determine the recommended dose of the combination of lapatinib with Lipo-Dox", 
            "measure": "Phase I part  recommended dose of the combination of lapatinib with Lipo-Dox", 
            "safety_issue": "No", 
            "time_frame": "Phase I:  6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658358"
        }, 
        "responsible_party": {
            "investigator_affiliation": "China Medical University Hospital", 
            "investigator_full_name": "Chang-Fang Chiu", 
            "investigator_title": "Vice Superintendent, Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "-Phase II part: To determined the objective response rate", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Phase II: 12 months"
        }, 
        "source": "China Medical University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "China Medical University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}